Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 4/2020

01-06-2020 | Schizophrenia | Original Paper

Cannabis use and psychosis: a review of reviews

Authors: Alkomiet Hasan, Rupert von Keller, Chris Maria Friemel, Wayne Hall, Miriam Schneider, Dagmar Koethe, F. Markus Leweke, Wolfgang Strube, Eva Hoch

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2020

Login to get access

Abstract

We conducted a systematic review of meta-analyses and systematic reviews to evaluate the impact of cannabis use on the onset and course of psychoses. Following a systematic literature search of five data bases (2005–2016) and consecutive structured evaluation, we were able to include 26 systematic reviews and meta-analyses. The methodological quality of the included publications were in the range of high and poor. The scientific literature indicates that psychotic illness arises more frequently in cannabis users compared to non-users, cannabis use is associated with a dose-dependent risk of developing psychotic illness, and cannabis users have an earlier onset of psychotic illness compared to non-users. Cannabis use was also associated with increased relapse rates, more hospitalizations and pronounced positive symptoms in psychotic patients. We make recommendations about the type of research that is required to better characterize the relationship between cannabis use and the development and outcomes of psychosis.
Appendix
Available only for authorised users
Literature
1.
Barkus E, Lewis S (2008) Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med 38:1267–1276PubMed
2.
Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79:549–556PubMed
3.
Martin-Santos R, Crippa JA, Batalla A et al (2012) Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 18:4966–4979PubMed
4.
Mechoulam R, Hanus LO, Pertwee R et al (2014) Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 15:757–764PubMed
5.
Gage SH, Zammit S, Hickman M (2013) Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep 5:2PubMedPubMedCentral
6.
Hill M (2015) Perspective: be clear about the real risks. Nature 525:S14PubMed
7.
Ksir C, Hart CL (2016) Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep 18:12PubMed
8.
Minozzi S, Davoli M, Bargagli AM et al (2010) An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev 29:304–317PubMed
9.
Di Forti M, Quattrone D, Freeman TP et al (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case–control study. Lancet Psychiatry 6:427–436PubMed
10.
Schoeler T, Monk A, Sami MB et al (2016) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3:215–225PubMed
11.
12.
D’souza DC, Sewell RA, Ranganathan M (2009) Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259:413–431PubMedPubMedCentral
13.
Bersani G, Orlandi V, Kotzalidis GD et al (2002) Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 252:86–92PubMed
14.
Hartz SM, Pato CN, Medeiros H et al (2014) Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71:248–254PubMedPubMedCentral
15.
Radhakrishnan R, Wilkinson ST, D’souza DC (2014) Gone to pot—a review of the association between cannabis and psychosis. Front Psychiatry 5:54PubMedPubMedCentral
16.
Falkai P, Rossner MJ, Schulze TG et al (2015) Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Mol Psychiatry 20:671–676PubMed
17.
Schmitt A, Malchow B, Hasan A et al (2014) The impact of environmental factors in severe psychiatric disorders. Front Neurosci 8:19PubMedPubMedCentral
18.
Bastian H, Glasziou P, Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 7:e1000326PubMedPubMedCentral
19.
Smith V, Devane D, Begley CM et al (2011) Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 11:15PubMedPubMedCentral
20.
Hoch E, Friemel C, Schneider M (2018) Cannabis: Potenzial und Risiko. In: Hoch E, Friemel C, Schneider M (eds) Eine wissenschaftliche Bestandsaufnahme. Springer, Berlin
21.
22.
Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration, London
23.
Hall W, Hoch E, Lorenzetti V (2019) Cannabis use and mental health: risks and benefits. Eur Arch Psychiatry Clin Neurosci 269:1–3PubMed
24.
Awmf (2012) German Association of the Scientific Medical Societies (AWMF). AWMF-Regelwerk “Leitlinien”. 1. Auflage. In: Standing Guidelines Commission. AWMF guidance manual and rules for guideline development sEEvAahwaola-rh (ed)
25.
Ocebm (2011) Levels of evidence working group. In: Oxford Centre for Evidence-Based Medicine O (ed), 2nd edn
26.
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedPubMedCentral
27.
Hemming K, Pinkney T, Futaba K et al (2013) A systematic review of systematic reviews and panoramic meta-analysis: staples versus sutures for surgical procedures. PLoS ONE 8:e75132PubMedPubMedCentral
28.
Sign (2015) Scottisch intercollegiate guidelines network 50 methodology checklist. Edinburgh, UK
29.
Burns JK (2012) Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des 18:5093–5104PubMed
30.
Koskinen J, Lohonen J, Koponen H et al (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130PubMed
31.
Kraan T, Velthorst E, Koenders L et al (2016) Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med 46:673–681PubMed
32.
Large M, Sharma S, Compton MT et al (2011) Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 68:555–561PubMed
33.
Linscott RJ, Van Os J (2013) An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 43:1133–1149PubMed
34.
Marconi A, Di Forti M, Lewis CM et al (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269PubMedPubMedCentral
35.
Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328PubMed
36.
Myles H, Myles N, Large M (2016) Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry 50:208–219PubMed
37.
Myles N, Newall H, Nielssen O et al (2012) The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des 18:5055–5069PubMed
38.
Potvin S, Sepehry AA, Stip E (2007) Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust N Z J Psychiatry 41:792–799PubMed
39.
Potvin S, Sepehry AA, Stip E (2006) A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 36:431–440PubMed
40.
Sara GE, Large MM, Matheson SL et al (2015) Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry 49:106–117PubMed
41.
Semple DM, Mcintosh AM, Lawrie SM (2005) Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19:187–194PubMed
42.
Szoke A, Galliot AM, Richard JR et al (2014) Association between cannabis use and schizotypal dimensions—a meta-analysis of cross-sectional studies. Psychiatry Res 219:58–66PubMed
43.
Baldacchino A, Hughes Z, Kehoe M et al (2012) Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. Am J Addict 21(Suppl 1):S88–S98PubMed
44.
Ben Amar M, Potvin S (2007) Cannabis and psychosis: what is the link? J Psychoact Drugs 39:131–142
45.
Cookey J, Bernier D, Tibbo PG (2014) White matter changes in early phase schizophrenia and cannabis use: an update and systematic review of diffusion tensor imaging studies. Schizophr Res 156:137–142PubMed
46.
Ferretjans R, Moreira FA, Teixeira AL et al (2012) The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Revista brasileira de psiquiatria 34(Suppl 2):S163–S177PubMed
47.
Geoffroy PA, Etain B, Houenou J (2013) Gene × environment interactions in schizophrenia and bipolar disorder: evidence from neuroimaging. Front Psychiatry 4:136PubMedPubMedCentral
48.
James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res 214:181–189PubMed
49.
Malchow B, Hasan A, Fusar-Poli P et al (2013) Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci 263:3–13PubMed
50.
Rapp C, Bugra H, Riecher-Rossler A et al (2012) Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des 18:5070–5080PubMedPubMedCentral
51.
Serafini G, Pompili M, Innamorati M et al (2012) Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des 18:5165–5187PubMed
52.
Vera U, Annarita T, Rocco P et al (2013) Cannabis and psychosis: a systematic review of genetic studies. Curr Psychiatry Rev 9:302–315
53.
Zammit S, Moore TH, Lingford-Hughes A et al (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 193:357–363PubMed
54.
Gage SH, Jones HJ, Burgess S et al (2017) Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med 47:971–980PubMed
55.
Buchanan RW, Kreyenbuhl J, Kelly DL et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93PubMed
56.
57.
Galletly C, Castle D, Dark F et al (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50:410–472PubMed
58.
Hasan A, Falkai P, Wobrock T et al (2015) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16:142–170PubMed
59.
Colizzi M, Murray R (2018) Cannabis and psychosis: what do we know and what should we do? Br J Psychiatry 212:195–196PubMed
60.
Ruther T, Bobes J, De Hert M et al (2014) EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 29:65–82PubMed
61.
Nielsen SM, Toftdahl NG, Nordentoft M et al (2017) Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med 47:1668–1677PubMed
62.
Hjorthoj C, Albert N, Nordentoft M (2018) Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry 75:733–739PubMedPubMedCentral
63.
Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong J-S, Ip HF, van der Zee MD, Bartels M, Day FR, Fontanillas P, Elson SL, de Wit H, Davis LK, MacKillop J, Derringer JL, Branje SJT, Hartman CA, Heath AC, van Lier PAC, Madden PAF, Maegi R, Meeus W, Montgomery GW, Oldehinkel AJ, Pausova Z, Ramos-Quiroga JA, Paus T, Ribases M, Kaprio J, Boks MPM, Bell JT, Spector TD, Gelernter J, Boomsma DI, Martin NG, MacGregor S, Perry JRB, Palmer AA, Posthuma D, Munafo MR, Gillespie NA, Derks EM, Vink JM (2018) GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature Neuroscience 21(9):1161–1170PubMedPubMedCentral
Metadata
Title
Cannabis use and psychosis: a review of reviews
Authors
Alkomiet Hasan
Rupert von Keller
Chris Maria Friemel
Wayne Hall
Miriam Schneider
Dagmar Koethe
F. Markus Leweke
Wolfgang Strube
Eva Hoch
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2020
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-019-01068-z

Other articles of this Issue 4/2020

European Archives of Psychiatry and Clinical Neuroscience 4/2020 Go to the issue

Editorial

Digital technology in psychiatry: towards the implementation of a true person-centered care in psychiatry?

Original Paper

Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study

Original Paper

The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer’s disease: a 9-year follow-up study

Letter to the Editor

Laying out the evidence for the persistence of neurogenesis in the adult human hippocampus

Original Paper

Analysis of KCNH2 and CACNA1C schizophrenia risk genes on EEG functional network modulation during an auditory odd-ball task

Short Communication

Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer’s disease: a pilot study